E

Exelixis

D
EXEL
USD
0.28
(0.7883%)
Market Closed
69,479.00
Volume
1.44
EPS
-
Div Yield
30.862
P/E
10,212,011,755.00
Market Cap
Today
0.7883%
1 Week
7.831%
1 Month
36.018%
6 Months
61.479%
12 Months
69.548%
Year To Date
49.198%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
GILD
GILD
6.23
(6.7946%)
USD
I
INCY
1.47
(1.8173%)
USD
A
ARRY
0.25
(4.223%)
USD
BMY
BMY
-0.57
(-1.0313%)
USD
S
SGEN
(%)
USD
ABBV
ABBV
-0.78
(-0.3876%)
USD

Title:
Exelixis

Sector:
Healthcare
Industry:
Biotechnology
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Do you need help or have a question?
Contact Us